Advanced HIV Disease
On this page
Direct answer
WHO defines advanced HIV disease (AHD) in adults and adolescents as a CD4 count below 200 cells/microlitre or a WHO clinical stage 3 or 4 condition — the zone where tuberculosis, cryptococcal disease, severe bacterial infections and Pneumocystis pneumonia cluster and where mortality concentrates in the first months after ART initiation. The AHD package is a checklist worth memorising: screen for TB and cryptococcal disease (urine TB-LAM and cryptococcal antigen testing at CD4 below 200), start cotrimoxazole prophylaxis, treat any active OI first, start ART rapidly (within days for most, deferred 4–6 weeks for cryptococcal meningitis and TB meningitis), and provide intensified adherence support and defaulter tracing. One in three people entering HIV care in high-burden settings still presents with AHD, which is why this package is now a NEET-PG-level concept.
What you must remember
- Definition: CD4 below 200 cells/microlitre or WHO stage 3/4 in adults and adolescents; all children under 5 with HIV are considered to have advanced disease.
- Screen with two tests at CD4 below 200 (or below 100 depending on setting): urine TB-LAM (detects lipoarabinomannan antigen in serious, disseminated TB) and serum/CSF cryptococcal antigen (CrAg).
- CrAg-positive without meningitis: preemptive fluconazole therapy (high-dose induction, then consolidation) before ART, preventing florid cryptococcal meningitis.
- TB screening at every contact: symptom screen (current cough, fever, weight loss, night sweats), Xpert ULTRA on sputum, urine LAM when CD4 is low, and empiric TB treatment when critically ill with strong suspicion.
- Cotrimoxazole prophylaxis and, where indicated, isoniazid preventive therapy after active TB is excluded.
- ART timing inside the package: start within 7 days (even within 2 days) for most AHD, within 2 weeks of TB treatment start, but delay about 4–6 weeks in cryptococcal meningitis and 4–8 weeks in TB meningitis.
- Fast-track the logistics: same-day CD4 or the minimum baseline panel, aggressive management of severe illness, and early palliative care engagement for those presenting moribund.
How to deploy the package in a real admission
A 30-year-old arrives with a month of fever, 8 kg weight loss and a CD4 of 68; the HIV diagnosis is new. Order the hour, not just the drugs. First, triage severity: vital signs, oxygen saturation, consciousness — shock or coma change the pathway to empiric sepsis therapy alongside evaluation. Second, run the two-screen: TB symptom screen is positive (fever, weight loss), so send sputum for Xpert and urine for TB-LAM, and draw blood for CrAg — in a CD4-68 Indian patient these two tests prevent the two commonest early deaths. Third, act on results in parallel: urine LAM positive means disseminated TB — start antitubercular therapy the same day; CrAg positive without neurological signs means preemptive fluconazole (with baseline lumbar puncture where feasible to exclude meningitis); CrAg with meningitis means amphotericin-flucytosine induction and ART delayed a month. Fourth, cover the rest: cotrimoxazole daily, screen for other stage-defining conditions (oral exam, chest radiograph, examination for Kaposi), test for hepatitis and syphilis, and give the first vaccine doses per immunisation-in-immunosuppression rules. Fifth, time the ART: within 2 weeks of TB therapy here, with intensive adherence counselling, and a return plan — the AHD patient who defaults in month one is the mortality statistic the package was built to prevent.
Where students slip
Three slips recur. The first is starting ART on day one reflexively for everyone — modern teaching is rapid, yes, but with named exceptions (cryptococcal and TB meningitis), and stems deliberately test the exception. The second is forgetting urine TB-LAM: sputum-negative, disseminated, immunosuppressed TB is exactly the phenotype LAM catches, and quoting it signals current reading. The third is treating CrAg positivity as a curiosity — preemptive fluconazole before ART is a specific, examinable intervention that prevents cryptococcal meningitis.
Frequently asked questions
How does WHO define advanced HIV disease in adults?
CD4 count below 200 cells/microlitre or a WHO clinical stage 3 or 4 event; all children below 5 years living with HIV are classified as having advanced disease.
Which two rapid screening tests anchor the AHD package at low CD4?
Urine tuberculosis-LAM for disseminated TB and serum cryptococcal antigen testing, both recommended at CD4 below 200 (or 100 depending on setting) at entry to care.
What follows a positive CrAg test without meningitis?
Preemptive antifungal therapy with high-dose fluconazole (after lumbar puncture where feasible to exclude meningitis), with ART deferred until the cryptococcal risk is controlled.
When should ART be delayed in advanced HIV disease?
In cryptococcal meningitis (about 4–6 weeks of antifungal therapy first) and tuberculosis meningitis (about 4–8 weeks), because early ART precipitates fatal immune reconstitution disease.
Why is cotrimoxazole given to every AHD patient regardless of CD4?
It prevents Pneumocystis pneumonia, cerebral toxoplasmosis, nontyphoidal salmonella bacteraemia, bacterial pneumonia and malaria, delivering a mortality benefit demonstrated in high-burden trials.